Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).
Drewe
E
E
Powell
R J
RJ
McDermott
E M
EM
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D001372:Aza Compounds / Q000008:administration & dosage; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D010505:Familial Mediterranean Fever / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000009:adverse effects* / Q000378:metabolism*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001372:Aza Compounds; D024841:Fluoroquinolones; D007074:Immunoglobulin G; D011804:Quinolines; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D000068879:Adalimumab; D000068800:Etanercept; D000077266:Moxifloxacin